Roche Shares Drop on Concern About Obesity Pill Side Effects.

Roche Holding AG's shares have dropped after its experimental obesity pill, known as CT-996, was linked to side effects such as nausea and vomiting in a small study. The results have raised concerns among investors about the drug's ability to compete with other weight loss medications in a market projected to reach $130 billion annually by the end of the decade. Roche argues that gradually increasing the dose could help mitigate side effects, but analysts believe it may take until 2030 for the company to bring its first weight loss drug to market. Novo Nordisk A/S and Eli Lilly & Co. are currently seen as the leaders in the weight loss market. [Extracted from the article]